|Founders:||Nickolaus Gravenstein, Donn Dennis, Tim Morey, Jerome Modell, and Dinesh Shah|
|Inventors:||Nickolaus Gravenstein, Donn Dennis, Tim Morey, Jerome Modell, and Dinesh Shah|
|Managers:||David L. Cooper (CEO), Nate Voss (COO)|
NanoMedex Pharmaceuticals, Inc. uses patented strategies to reformulate fat- or lipid-soluble drugs so they can be dissolved in water and administrated intravenously. Intravenous administration offers a variety of benefits to patients, physicians, and health care providers.
NanoMedex's first product is Microfol™, a new formulation of propofol, a widely used anesthetic.
Nickolaus Gravenstein, M.D., Donn Dennis, M.D., Tim Morey, M.D., Jerome Modell, M.D. and Dinesh Shah, M.D., are the co-founders of NanoMedex Pharmaceuticals, Inc. While employed at the University of Florida-Gainesville, they invented the formulation strategy upon which the company's products are built.
Drs. Gravenstein and Morey continue to serve on NanoMedex's Board of Directors.
David L. Cooper, M.D., Ph.D. is President and CEO of NanoMedex Pharmaceuticals, Inc.
Before joining NanoMedex, David was Chief Medical Officer of Nimblegen, which was recently sold to Roche, and Vice President of Quest Diagnostics. David also provided product development services to the Marshfield Clinic for three years.
Nate Voss is Chief Operating Officer of NanoMedex Pharmaceuticals.
Before joining NanoMedex, Voss worked for Baker Tilly Virchow Krause, where he provided a broad array of financial advisory services, including mergers and acquisitions, debt and equity financing, tax credit financing, and business valuations.
Latest Fund News
- Kegonsa Seed Fund Sells Second Portfolio Company
- Ken Johnson Looks for Seeds of Success
- Three Kegonsa Seed Fund Companies Selected as 2010 Wisconsin Companies to Watch
- Kegonsa Seed Fund Experiences First Portfolio Company Exit
- Kegonsa Seed Fund Named to Entrepreneur's VC Top 100
- Kegonsa Seed Fund Launched